Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C treatment

    Effective direct-acting antiviral or 'DAA' medicines, used without interferon, can now cure most people with hepatitis C. This includes people who previously were considered to be more difficult...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    DAAs target different steps of HCV reproduction. These include HCV protease inhibitors, polymerase inhibitors and NS5A inhibitors. Recommended regimens include at least two drugs that work in different...

    From: Booklets

    Information level Level 2
  • Treatment for people with HIV and HCV co-infection

    In the UK, standards for HIV treatment and care are set and monitored by the British HIV Association (BHIVA), the professional association for HIV doctors and other healthcare...

    From: Booklets

    Information level Level 2
  • Hepatitis C and HIV

    Hepatitis C is a blood-borne infection that is transmitted in some of the same ways as HIV.Over time untreated hepatitis C...

    From: Factsheets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

    A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

    19 February 2018 | Nasdaq
  • Hepatitis C drugs not being accessed by thousands of Australians with the disease

    Hundreds of thousands of Australians with hepatitis C are failing to access new curative drugs, despite the Government subsidising them at huge cost to the taxpayer. The trend means the Government is at risk of missing its target to eradicate hepatitis C and of spending far more than necessary on the treatments.

    12 February 2018 | ABC News
  • Among Those With HIV, Certain Factors Lower Chance of Curing Hep C

    These include a low CD4 count, having cirrhosis and taking certain hep C drug regimens.

    06 February 2018 | Poz
  • Can England really eliminate hepatitis C by 2025?

    The World Health Organisation set a goal to eliminate hepatitis C by 2030. The NHS recently announced that it will go one better than that: it will eliminate the disease in England by 2025. In theory, the goal is achievable, but there are still significant challenges to overcome.

    05 February 2018 | The Conversation UK
  • Georgia: 98% of people in Hepatitis C elimination program cured

    Around 45,000 people have gone through medical treatment for Hepatitis C in Georgia, 98 percent of which were cured, the head of Georgia’s National Center for Disease Control and Public Health (NCDC) Amiran Gamkrelidze said.

    31 January 2018 | Agenda.ge
  • NHS England sets out plans to be first in the world to eliminate Hepatitis C

    England could be the first country in the world to eliminate Hepatitis C, under ambitious plans announced by the NHS today.

    29 January 2018 | NHS England
  • Managing the Fruits of HCV Cure: How Much Care do the Cured Need?

    An additional dimension of HCV infection about which our knowledge has dramatically expanded is the potential for extrahepatic morbidity and mortality associated with HCV infection, and the opportunity to ameliorate or prevent such outcomes by effecting virologic cure — problems such as diabetes, atherosclerosis, renal disease, cryoglobulinemia, lymphoma and others.

    22 January 2018 | Healio
  • India to launch national program to control viral hepatitis and aims to negotiate lower drug prices

    The health ministry is set to roll out a National Program for the Control of Viral Hepatitis from the 2018-19 financial year. An antiviral treatment that costs anywhere between $63,000 and $94,000 for the full course in the USA and Europe is to be provided free of cost at all government health organizations.

    09 January 2018 | Pharma Letter
  • England: 25,000 Hepatitis C patients receive new treatments

    As we go into the New Year, the Hepatitis C (HCV) programme is set to pass a major milestone. The number of patients in England having received the new direct acting antiviral treatments will pass the 25,000 mark. The 22 Operational Delivery Networks (ODNs) across the country were tasked to expand rates of treatment by 25 per cent from April this year, and nine months on are delivering at over 90 per cent of those goals.

    08 January 2018 | NHS England
  • HCV Genotype 6 Responds to 8-Week Oral Treatment

    The successful treatment of hepatitis C virus genotype 6 (HCV-GT6) with a non-interferon-based fixed dose oral regimen of ledipasvir and sofosbuvir (LDV/SOF) bodes well for treating HCV in Southeast Asia, where newer pangenotypic agents are not available to treat this region's most prevalent genotype.

    02 January 2018 | MD
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.